Used to produce a mucoid exo-polysaccharide vaccine
Opportunistic pathogen research
Respiratory research
Isolation
Sputum from a cystic fibrosis patient, Boston, MA
Biosafety Level
2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.
Product Format
freeze-dried
Storage Conditions
Frozen: -80°C or colder Freeze-Dried: 2°C to 8°C Live Culture: See Propagation Section
Disclosure
This material is cited in a US or other Patent and may not be used to
infringe the claims. Depending on the wishes of the Depositor, ATCC may be
required to inform the Patent Depositor of the party to which the material was
furnished. This material may not have been produced or characterized by ATCC.
Pier GB. Mucoid exopolysaccharide vaccine against Pseudomonas aeruginosa. US Patent 4,578,458 dated Mar 25 1986
Pier GB, et al. Immunochemical characterization of the mucoid exopolysaccharide of Pseudomonas aeruginosa. J. Infect. Dis. 147: 494-503, 1983. PubMed: 6220094
